Orforglipron is an oral, non-peptide, small-molecule GLP-1 receptor agonist developed as a weight loss drug by Eli Lilly and Company. It was discovered by Chugai Pharmaceutical Co., then was licensed to Lilly in 2018.
Orforglipron is easier to produce than existing peptide GLP-1 agonists and is expected to be cheaper. From Wikipedia
